28013205|t|Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues
28013205|a|The aim was to establish the prevalence and severity of faecal incontinence (FI) in SSc, its association with other intestinal manifestations and potential predictors of FI, and its impact on quality of life. A multicentre, cross-sectional study of 298 SSc subjects followed in the Canadian Scleroderma Research Group cohort was performed using validated questionnaires: Jorge-Wexner score (an FI severity scale), Bristol stool scale (a visual scale of stool consistency) and FI Quality-of-Life scale. Constipation was defined by the Rome III criteria. Associations between the Jorge-Wexner score and other clinical variables were determined using multivariate regression analyses. Eighty-one (27.2%) subjects had FI, which was mild in 37 (12.4%) and moderate to severe in 44 (14.8%). Most patients had well-formed stools, 111 (38.8%) reported constipation and 38 (13.4%) had been previously treated for small intestinal bacterial overgrowth (SIBO). Variables independently associated with FI were: loose vs well-formed stools [odds ratio (OR) = 7.01, 95% CI: 2.09, 23.51)], constipation (OR = 3.64, 95% CI: 1.61, 8.27, P = 0.002), history of SIBO (OR = 2.97, 95% CI: 1.06, 8.27) and urinary incontinence (OR = 2.45, 95% CI: 1.14, 5.27). Quality of life measured with the FI Quality-of-Life scale was inversely correlated with FI severity (correlation coefficients between -0.602 and -0.702, P < 0.001). FI was common and often severe in SSc. Loose stools, SIBO, constipation and urinary incontinence were strongly associated with FI. Other than targeting anorectal dysfunction, concomitant treatment of clinical correlates could lead to improvement in FI and quality of life in SSc.
28013205	23	42	faecal incontinence	T038	UMLS:C0015732
28013205	46	64	systemic sclerosis	T038	UMLS:C0036421
28013205	154	173	faecal incontinence	T038	UMLS:C0015732
28013205	175	177	FI	T038	UMLS:C0015732
28013205	182	185	SSc	T038	UMLS:C0036421
28013205	214	224	intestinal	T017	UMLS:C0021853
28013205	268	270	FI	T038	UMLS:C0015732
28013205	322	343	cross-sectional study	T062	UMLS:C0010362
28013205	351	354	SSc	T038	UMLS:C0036421
28013205	380	415	Canadian Scleroderma Research Group	T092	UMLS:C1708333
28013205	416	422	cohort	T098	UMLS:C0599755
28013205	453	467	questionnaires	T170	UMLS:C0034394
28013205	469	487	Jorge-Wexner score	T170	UMLS:C0349674
28013205	492	494	FI	T038	UMLS:C0015732
28013205	495	509	severity scale	T170	UMLS:C0681887
28013205	512	531	Bristol stool scale	T170	UMLS:C4084861
28013205	551	568	stool consistency	T033	UMLS:C0426740
28013205	574	576	FI	T038	UMLS:C0015732
28013205	577	598	Quality-of-Life scale	T170	UMLS:C0451401
28013205	600	612	Constipation	T033	UMLS:C0009806
28013205	632	649	Rome III criteria	T170	UMLS:C0679228
28013205	676	694	Jorge-Wexner score	T170	UMLS:C0349674
28013205	705	723	clinical variables	T033	UMLS:C1836458
28013205	746	778	multivariate regression analyses	T170	UMLS:C0034980
28013205	812	814	FI	T038	UMLS:C0015732
28013205	913	919	stools	T031	UMLS:C0015733
28013205	942	954	constipation	T033	UMLS:C0009806
28013205	1002	1039	small intestinal bacterial overgrowth	T038	UMLS:C3160854
28013205	1041	1045	SIBO	T038	UMLS:C3160854
28013205	1088	1090	FI	T038	UMLS:C0015732
28013205	1097	1102	loose	T033	UMLS:C2129214
28013205	1118	1124	stools	T031	UMLS:C0015733
28013205	1173	1185	constipation	T033	UMLS:C0009806
28013205	1241	1245	SIBO	T038	UMLS:C3160854
28013205	1282	1302	urinary incontinence	T038	UMLS:C0042024
28013205	1370	1372	FI	T038	UMLS:C0015732
28013205	1373	1394	Quality-of-Life scale	T170	UMLS:C0451401
28013205	1425	1427	FI	T038	UMLS:C0015732
28013205	1502	1504	FI	T038	UMLS:C0015732
28013205	1536	1539	SSc	T038	UMLS:C0036421
28013205	1541	1553	Loose stools	T033	UMLS:C2129214
28013205	1555	1559	SIBO	T038	UMLS:C3160854
28013205	1561	1573	constipation	T033	UMLS:C0009806
28013205	1578	1598	urinary incontinence	T038	UMLS:C0042024
28013205	1629	1631	FI	T038	UMLS:C0015732
28013205	1664	1675	dysfunction	T038	UMLS:C0277785
28013205	1689	1698	treatment	T058	UMLS:C0087111
28013205	1751	1753	FI	T038	UMLS:C0015732
28013205	1777	1780	SSc	T038	UMLS:C0036421